Research Article
Capecitabine and Temozolomide in Neuroendocrine Tumor of Unknown Primary
| Characteristic | Number |
| Total patients with NET | 56 | Total patients treated with CAPTEM | 12 | Median age | 62 years | Male : female ratio | 1 : 1 | Mean duration of treatment before progression | 10.8 months | CAPTEM used as front-line systemic therapy | 9 patients | Median chromogranin A | 221 | Concomitant Somatostatin analogues use | 5 patients | Grade I | 1 | Grade II | 7 | Grade III | 4 |
|
|